IL SB1934

Allows pharmacists to substitute FDA-approved interchangeable biosimilar products for prescribed biological products, subject to specified conditions.

Requires the prescribing physician to not prohibit substitution in writing, orally, or electronically using procedures consistent with existing pharmacy law Section 25.

Mandates that pharmacies inform patients of biosimilar substitutions and notify the prescriber within 5 business days with the name and manufacturer of the dispensed biosimilar.

Requires pharmacies to maintain written records of all biosimilar substitutions for at least 5 years.

Directs the Board to adopt rules implementing these biosimilar substitution provisions, effective immediately upon passage.